Tim
por Kojo MullerHello, my name is Timothy Niina, and I want to talk to you about Cognitive Stimulation Therapy (CST) for supporting people living with Parkinson’s disease.
In this presentation, I will delve into five interrelated domains:
Alzheimer’s disease biology and epidemiology,
A clinical contrast with Lewy Body dementia,
A practical case study involving Beryl, a 93-year-old woman living in the West Midlands diagnosed with Alzheimer’s disease, and how CST supports her,
The legal and ethical frameworks guiding decision-making,
And a critical evaluation of evidence-based interventions, focusing on CST.
________________________________________
1. What is Alzheimer’s Disease?
Alzheimer’s disease is a progressive neurodegenerative condition that affects the brain and leads to problems with memory, thinking, behaviour, and the ability to carry out daily activities. It is the most common form of dementia and gradually worsens over time as brain cells are damaged and die (Alzheimer’s Society, 2024).
More than simple age-related forgetfulness, Alzheimer’s disease has a distinct biological signature. At the molecular level, it is characterised by the extracellular accumulation of amyloid-β peptides forming senile plaques, and intracellular aggregation of hyperphosphorylated tau protein in neurofibrillary tangles. These pathological hallmarks initiate a cascade of synaptic dysfunction, neuroinflammation, and ultimately neuronal death, first targeting the hippocampus and entorhinal cortex — the brain’s epicentres for memory and spatial orientation (Alzheimer’s Society, 2024).
Clinically, Alzheimer’s begins with subtle short-term memory lapses — misplaced keys, missed appointments, and word-finding difficulties. Over time, it progresses to include executive dysfunction, visuospatial impairment, and personality changes.
Epidemiologically, Alzheimer’s accounts for 60–70% of all dementia cases worldwide, affecting over 900,000 people in the UK, a figure expected to rise by 40% in the next 15 years as life expectancy increases (Alzheimer’s Research UK, 2024).
________________________________________
Globally, dementia affects an estimated 55 million people, with Alzheimer’s disease accounting for up to 70% of these cases. The World Health Organization (2023) projects that by 2050, this number will rise to over 139 million, placing unprecedented strain on healthcare systems worldwide.
In the UK alone, the economic cost of dementia is estimated at £25 billion annually, including both formal care and unpaid informal care by families.
Beyond numbers, Alzheimer’s creates emotional, social, and ethical burdens. People living with dementia often face stigma and misunderstanding, while carers experience burnout, depression, and financial strain. Understanding this broader impact is key to creating compassionate, comprehensive care.
________________________________________
2. Alzheimer’s vs. Lewy Body Dementia
Though both lead to cognitive decline, Alzheimer’s and Lewy Body dementia (LBD) differ in pathology and clinical course.
In LBD, α-synuclein proteins misfold and aggregate into Lewy bodies within cortical and subcortical neurons. These affect attention, perception, and motor function, leading to symptoms like fluctuating cognition, visual hallucinations, and Parkinsonian signs such as rigidity or tremor.
Alzheimer’s follows a steadier course, dominated by progressive memory impairment (McKeith et al., 2017).
________________________________________
2a. Diagnostic Challenges in LBD
Despite available criteria, LBD is often misdiagnosed, especially as Alzheimer’s, depression, or Parkinson’s disease. The use of typical antipsychotics can cause severe sensitivity reactions in LBD patients, making accurate diagnosis critical.
Additionally, standard cognitive tests often fail to capture LBD’s fluctuating symptoms, requiring longitudinal assessments and tools like DaT-SCAN imaging.
________________________________________
3. Case Study: Beryl
Let’s consider Beryl, a 93-year-old woman diagnosed with Alzheimer’s five years ago. Her decline has been gradual and memory-focused, never including hallucinations or motor symptoms. This consistent memory deterioration aligns more closely with classical Alzheimer’s than with LBD.
________________________________________
3a. Beryl’s Psychosocial Context
Beryl lives alone in the West Midlands. Her daughter visits once a week. Once active in her church, Beryl has slowly disengaged due to difficulty following conversations and remembering names. She now experiences mild depression, loneliness, and struggles with medication routines.
Without intervention, Beryl risks faster cognitive decline and institutionalisation. Her case underscores the importance of timely, person-centred interventions like CST.
________________________________________
4. Legal and Ethical Frameworks
Dementia care is guided by multiple statutes:
The Mental Capacity Act (2005) starts from the presumption of capacity and advocates for least restrictive choices (UK Government, 2005).
The Care Act (2014) emphasises prevention, wellbeing, and personalised planning (Care Act, 2014).
The Human Rights Act (1998) protects rights to liberty, privacy, and dignity (Human Rights Act, 1998).
NICE Guideline NG97 (2018) translates these into practical recommendations (NICE, 2018).
________________________________________
4a. Ethical Tensions: Autonomy vs Safety
Beryl wants to walk to the shops. Her family fears she’ll get lost. Should her keys be taken? Should the door be locked?
The Mental Capacity Act encourages creative alternatives, like wearable GPS or participation in safe-walking schemes. These support safety without denying autonomy.
________________________________________
5. Evidence-Based Interventions
Pharmacological
Drugs like donepezil and memantine may modestly improve symptoms but come with side effects like nausea or confusion (NICE, 2018).
________________________________________
Non-Pharmacological
Reminiscence therapy: uses memories and sensory triggers to evoke emotion.
Validation therapy: focuses on feelings over facts.
Reality orientation: repeatedly reorients people to time, place, and identity.
________________________________________
5a. Why I Chose CST
Cognitive Stimulation Therapy (CST) stands out as the NICE-recommended gold standard for mild to moderate dementia. It includes 12 group sessions covering themes like current affairs, language, and creativity.
In a landmark study, Spector et al. (2003) found CST led to a 2.5-point MMSE improvement. Participants reported greater confidence, mood, and engagement.
________________________________________
Pros of CST
Evidence-based
Social and cognitive benefits
Cost-effective
Adaptable (group or 1:1)
Cons
May overwhelm those with severe dementia
Less effective without continuity
Group dynamics can be challenging
________________________________________
5b. Cultural and Practical Considerations
A typical CST session includes:
Orientation to time/place
Group discussions (e.g., music, food, holidays)
Creative tasks and games
To be effective, CST must be culturally relevant — adapting topics and materials to individual backgrounds. In underfunded or rural areas, digital CST may be the future, but access remains limited.
________________________________________
6. Broader Reflection and Future Directions
This topic highlights the need for:
Ongoing training in dementia communication and trauma-informed care
Flexible delivery of therapies
More research into CST’s long-term and digital effectiveness
________________________________________
🧩 Conclusion
In this presentation, I have:
Defined Alzheimer’s disease
Differentiated it from LBD using Beryl’s case
Discussed the legal and ethical frameworks influencing care
Compared interventions
And made the case for CST as a person-centred, evidence-based choice
CST offers people like Beryl not just improved cognition — but dignity, engagement, and a better quality of life.
Thank you for your attention.